Status:
UNKNOWN
Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success
Lead Sponsor:
Cairo University
Conditions:
Symptomatic Irreversible Pulpitis
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
To assess the anesthetic success of inferior alveolar nerve block (IANB), intraoperative pain intensity and need for supplemental anesthesia on administration of 1.8ml or 3.6ml 2% mepivacaine IANB, or...
Detailed Description
Patients with moderate-to-severe preoperative pain related to mandibular molars with symptomatic irreversible pulpitis will be included. Patients receive 1.8 ml, 3.6 ml 2% mepivacaine IANB, or 1.8ml 2...
Eligibility Criteria
Inclusion
- Patients in good health (ASA Class I, II).
- Age between 18-60 years old.
- Males or females.
- Mandibular molar teeth diagnosed with symptomatic irreversible pulpitis.
- Patients who can understand NRS scale and sign the informed consent.
Exclusion
- Patients who had used any type of analgesic medication during the preceding 8 hours before the treatment.
- Pregnant or nursing females.
- Patients with a contraindication for the use of mepivacaine, articaine or any used drug or material.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05238727
Start Date
March 1 2022
End Date
September 1 2023
Last Update
February 14 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.